bpc 157 spinal cord injury study Stable gastric pentadecapeptide can improve the healing course of and lead to functional recovery in rats Peptide therapy with pentadecapeptide BPC

Kolik LG, Nadorova AV, Antipova TA et al (2019) Selank, peptide analogue of tuftsin, protects against ethanol-induced memory impairment by regulating of BDNF content in the hippocampus and prefrontal cortex in rats

The primary endpoint was AUC 0 for plasma cagrilintide from baseline (day 1) to day 39 (end of study)

Currently, multiple phase 3 trials with oral semaglutide and orforglipron are ongoing for different populations (NCT05803421), while another oral GLP-1 RA (CT-996) is in early phase clinical trials (Table 1)

Several factors support the theoretical viability of oral BPC-157, though human outcomes remain unproven: Gastric Stability: BPC-157 was originally studied for gastric protection in animal models, meaning the compound was administered directly into the stomach in research settings

But getting it wrong changes everything downstream